Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer

Schoenlein, Patricia V.; Hou, Min; Samaddar, Julia S.; Gaddy, Virgil T.; Thangaraju, Muthusamy; Lewis, Jill B.; Johnson, Maribeth; Ganapathy, Vadivel; Kallab, Andre M.; Barrett, J.

doi:10.3892/ijo.31.3.643

Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer

NobleIDNI3P29W18R22S96

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/8698CEEB.svg?ark=w1%2F20260525%2F8698CEEB&value=id)](https://nobleid.org/work/w1/20260525/8698CEEB)

ARK Inflections

Metadata (JSON)Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Patricia V. Schoenlein

Claim authorship of this work

Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer

NobleIDNI3P29W18R22S96

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/8698CEEB.svg?ark=w1%2F20260525%2F8698CEEB&value=id)](https://nobleid.org/work/w1/20260525/8698CEEB)

ARK Inflections

Metadata (JSON)Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Patricia V. Schoenlein

Claim authorship of this work